Cost-Effectiveness of Baloxavir Marboxil Versus Oseltamivir or no Treatment for the Management of Influenza in the United States.

Svenn Alexander KommandantvoldShih-Chen ChangAndy SurinachVincent YauJennie H BestHassan ZaraketHao ZhouJeff FrimpterMarie-Helene Blanchet Zumofen

Published in: Infectious diseases and therapy (2024)

Baloxavir was cost-effective compared with oseltamivir or no antiviral treatment. The potential of baloxavir to reduce viral transmission offers a substantial economic benefit from a US payer perspective.

Keyphrases

combination therapy
climate change
human health
replacement therapy